Committees

Medicines Assesment Advisory Committee

1	Welcome
2	Apologies
3	Declaration of conflicts of interest
4	Tecentriq, atezolizumab (60 mg/mL), concentrate for dilution and infusion (Roche).
	Tecentriq is a concentrate for dilution and infusion and contains the active ingredient atezolizumab (60mg/mL). Tecentriq is currently approved for a number of therapeutic indications in New Zealand including triple-negative breast cancer (TNBC). The conditions of Tecentriq’s indication for TNBC is as follows: Tecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease. This application is being referred to the Committee for independent advice as to whether the therapeutic indication for TNBC specified above remains appropriate for Tecentriq.
5.	GENERAL BUSINESS
6.	DATE OF NEXT MEETING